Experience of the use of zoledronic acid (Rezoklastin 5 mg/6.25 ml, OOO «NATIVA») in patients with low bone mineral density in the settings of the center for prevention of osteoporosis of Novosibirsk SRITO

The purpose of this work was to evaluate bone mineral density (BMD) at 2, 3, 4, 5 and 6 years of the use of zoledronic acid (Rezoklastin 5 mg/6.25 mL) in patients with osteopenia and osteoporosis. We examined 60 postmenopausal women aged 48-76 with low BMD (T-criterion from -2.6 to -4.5 SD). The following basic methods of research were used: clinical; sociological; X-ray; densitometric (osteodensitometer HOLOGIC, QDR, Discovery-A, USA); and statistical methods. The main results of the work were good tolerability of the drug; absence of fractures during observation period; an increase in BMD in all patient groups and across all regions.

zoledronic acid, osteopenia, osteoporosis, bone mineral density, fractures, Rezoklastin